Why the study?
ANGPTL8 regulates triglycerides and has emerged as a potential biomarker for steatosis or steatohepatitis, prompting a synthesis of evidence regarding its association with NAFLD, MAFLD, or MASLD.
Are circulating ANGPTL8 concentrations elevated in adults with steatotic liver disease related to metabolic dysfunction compared to controls?
Are circulating ANGPTL8 concentrations elevated in adults with steatotic liver disease related to metabolic dysfunction compared to controls?
Adults with steatotic liver disease related to metabolic dysfunction exhibit significantly higher circulating ANGPTL8 concentrations compared to controls, highlighting its potential as a diagnostic biomarker.
Answers are grounded in this paper and cite their sources.
The abstract and key finding are incomplete — I’ll locate the full meta-analysis so the implication can be written from the actual primary result.I have the paper; next I’ll pull the abstract, primary endpoint, and conclusions so the implication tracks the actual verdict.Should not yet change MASLD screening; leaves open ANGPTL8’s biomarker utility pending prospective, lower-bias studies.
Background: Steatotic liver disease related to metabolic dysfunction is the most common cause of chronic liver disease globally. The spectrum of this condition includes steatosis and steatohepatitis and was previously referred to as non-alcoholic fatty liver disease (NAFLD) but has been renamed as metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently as metabolic dysfunction-associated steatotic liver disease (MASLD). Angiopoietin-like protein 8 (ANGPTL8), also known as betatrophin or lipasin, regulates triglycerides and has emerged as a potential novel biomarker for steatosis/steatohepatitis. Therefore, this systematic review aimed to identify and synthesize the evidence on the possible association of circulating ANGPTL8 concentrations with NAFLD, MAFLD or MASLD. Methods: PubMed/MEDLINE, Cochrane Library, EMBASE, and Web of Science were searched for studies published in English reporting circulating ANGPTL8 concentrations in adults with NAFLD or MAFLD or MASLD and controls. A meta-analysis was performed, reporting the standardized mean difference (SMD) of circulating ANGPTL8 concentrations between these two groups. Study quality and risk of bias were assessed using the NIH quality assessment tool and RoBANS 2, respectively. Results: 352 controls). Circulating ANGPTL8 concentrations were significantly higher in patients with NAFLD or MAFLD compared with controls (SMD: 0.62, 95%CI: 0.28-0.97; p<0.001). Considerable heterogeneity was noted among these studies, with six studies having high risk of bias in at least one RoBANS 2 domain. Conclusion: These findings present up-to-date comprehensive evidence indicating that adults with steatotic liver disease related to metabolic dysfunction exhibit higher circulating ANGPTL8 concentrations compared with controls. Given the need for novel screening/diagnostic biomarkers for steatosis/steatohepatitis, as well for additional drug targets, large and prospective studies are required to confirm this association and explore its temporal direction, particularly under the new MASLD diagnosis/term.
No takes yet. Share an insight, caveat, or question.
Abdelhameed et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: